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Introduction
Antidepressants are an evidence-based treatment 
for depressive and anxiety disorders.1–4 However, 
with prescribing of antidepressant drugs rising 
exponentially,5 the appropriateness of these pre-
scriptions has been questioned.6–8
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Abstract
Background: Long-term antidepressant use has increased exponentially, though this is not 
always according to guidelines. Our previous randomized controlled trial (RCT) showed that 
participants using antidepressants long term without a proper indication were apprehensive 
to stop: only half were willing to attempt to discontinue their antidepressant use. The objective 
of this study was to explore participants’ barriers and facilitators for stopping long-term 
antidepressant use without a current proper indication.
Methods: Semistructured interviews with participants from the intervention group of our 
RCT, a cluster-RCT in general practice in the Netherlands. The latter study was a stop trial 
with patients on long-term antidepressant use without a current indication (no psychiatric 
diagnosis). Participants of the intervention group of the RCT had been provided with advice to 
stop antidepressants. Participants of the current interview study were purposively sampled 
(from the intervention group of the RCT) to ensure diversity in age, sex, and intention to 
discontinue the antidepressant. Analysis was performed as an iterative process, based on the 
constant comparative method. Data collection proceeded until saturation was reached.
Results: A total of 16 participants were interviewed. Fear (of recurrence, relapse, or to disturb 
the equilibrium) was the most important barrier; prior attempts fueled these anticipations. 
Also prominent as a barrier was the notion that antidepressants are necessary to counter a 
deficiency of serotonin. Facilitators were information on duration of usage given at the time 
of first prescription and confidence in a successful attempt. We found many participants 
struggling between barriers and facilitators to discontinue and participants not discontinuing 
while experiencing no barriers (ambivalence).
Conclusion: Fear is an important motive for patients considering discontinuation of 
antidepressants. Serotonin deficiency as explanation for antidepressant effectiveness 
promotes life-long use and hinders discontinuation of antidepressant treatment. The prospect 
of discontinuation at first prescription can facilitate a future discontinuation attempt. General 
practitioners should be aware of their patients’ fears, expectations, and attributions toward 
antidepressant use/discontinuation, and of new developments in taper methods.
Keywords: antidepressant agents, anxiety disorder, depressive disorder, discontinuation, 
general practice, inappropriate prescribing, primary health care
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A number of factors have been suggested to con-
tribute to the increasing numbers of antidepres-
sant prescriptions, including increased prevalence 
and improved recognition and management. 
Long-term usage has been found to contribute 
greatly to the growing amount of antidepressant 
use.6,9,10 Guidelines on the duration of long-term 
antidepressant prescriptions differ in detail, but, 
in general, recommend continuing medication 
after adequate first response. The duration of this 
continuation is set at between 6 and 12 months, 
depending on the guideline.1,4,11 Maintenance 
therapy is recommended for patients with recur-
rent depression, with recurrent being defined as 
either two or three episodes.1,4,11 Maintenance 
therapy could also be suggested for patients with 
other risk factors for relapse. Although guidelines 
concerning antidepressant treatment duration are 
based mainly on consensus rather than evidence, 
and although the advice for a certain duration of 
the treatment is not the same as advice to stop 
treatment after that period, general practitioners 
(GPs) are strongly committed to stop drug ther-
apy when not strictly indicated.
We therefore sought to minimize long-term 
(⩾9 months) antidepressant usage without cur-
rent indication with our RCT.12,13 This study 
demonstrated the difficulty in discontinuing long-
term antidepressant use without current indica-
tion. Participants were reluctant to accept 
discontinuation advice despite continued use of 
the antidepressant not being deemed congruent 
with clinical guidelines.3,4 In almost half of the 
cases the discontinuation advice was rejected by 
the participant. Of course, patients might, in 
hindsight, actually be right not to stop treatment, 
but there is insufficient evidence about this 
problem.
Patients’ experiences of antidepressant use were 
summarized in a large meta-ethnography.14 In 
summary, patients constantly evaluate their anti-
depressant use by balancing risks and benefits, 
hopes and fears, and positive and negative self-
images. A tension was found between ‘feeling 
well’ and ‘being well’, further described as the dif-
ference between self-determination and psycho-
logical dependency. When focusing on long-term 
antidepressant users, antidepressants were seen 
as a threat to autonomy. Antidepressants doubled 
the stigma, with the antidepressant as the evi-
dence of failure to cope with everyday problems. 
On the other hand, antidepressant use also 
reduced stigma, with depression being seen as a 
physical illness and the ‘serotonin deficiency’ 
being treated with antidepressants. This was con-
gruent with a general belief that the neurotrans-
mitter ‘serotonin’ played in important role in the 
development of depression. The fear of relapse 
and withdrawal symptoms is considered more 
frightening than the prospect of continuing 
unnecessary medication, leading to continued 
use: ‘better safe than sorry’.15 Some patients 
believe their condition to be chronic and requir-
ing of life-long treatment, while at the same time 
feeling uncomfortable with this prospect.15–17 
Research on nonadherence to antidepressants 
(after initial acute phase treatment) has found 
similar beliefs: harmful beliefs and necessity 
beliefs are weighed, and this trade-off results in 
adherence.18–20 At the time this study was 
designed, it was unknown whether patients using 
long-term antidepressants without a current indi-
cation for continued use have the same attitudes 
towards their use.
With this study, we aimed to explore the attitudes 
of these specific patients, who are using antide-
pressants long term without a proper current 
indication, towards the discontinuation of these 
drugs, and to explore their attitudes towards the 
discontinuation advice they received when par-
ticipating in the RCT.12,13 We were looking for 
experiences and cognitions of patients towards 
which counseling to discontinue antidepressant 
use without indication according to guidelines 
could be directed.
Methods
Design
We performed a qualitative study using in-depth 
semistructured interviews. The study was exempt 
from evaluation by the institutional ethics com-
mittee, as it was considered an addition to the 
approved RCT (Institutional Ethics Committee 
Nijmegen registration number NL29718.091.09). 
Both the current qualitative study and the RCT 
were performed in the Netherlands between 2010 
and 2014. We reported this study according to 
the consolidated criteria for reporting qualitative 
research (COREQ) guidelines.
Participants
Participants were selected from our cluster-RCT 
on long-term antidepressant use.12,13 This RCT 
included patients who used antidepressants for 
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9 months or longer, that is, long-term antidepres-
sant users. These patients underwent a psychiat-
ric diagnostic evaluation to determine whether 
they still had an indication for antidepressant use 
according to the clinical multidisciplinary guide-
lines in the Netherlands.3,4 Patients were excluded 
from the RCT in case of: current treatment in a 
psychiatric in- or outpatient clinic; indication for 
use of long-term antidepressants according to the 
Dutch guidelines for depressive and anxiety dis-
orders [i.e. a history of recurrent depression (⩾3 
episodes) or a recurrent psychiatric disorder with 
at least two relapses after antidepressant discon-
tinuation]; history of psychosis, bipolar disorder, 
or obsessive compulsive disorder; current diagno-
sis of substance use disorder (including tobacco); 
nonpsychiatric indication for long-term antide-
pressant usage, for example, neuropathic pain; 
hearing impairment or insufficient understanding 
of the Dutch language.
Patients who had been assigned to the interven-
tion group in the RCT were selected for this qual-
itative study.13 Thus, only those patients using 
antidepressants long term (⩾9 months) without a 
current indication for continued usage were 
included. These patients had received from their 
GP the recommendation to discontinue their 
antidepressant use. We had provided the GP with 
information about the current diagnosis and the 
method for discontinuing the medication. Patients 
who did not consent to be contacted for further 
research after the RCT were not approached for 
participation in the current interview study (24%, 
n = 17/70). Participants were purposively sampled 
to ensure diversity in age, sex, the intention to 
comply with the advice, and actual discontinua-
tion of the antidepressant during the course of the 
RCT. The GPs played no role in the sampling 
procedure. Data collection proceeded until satu-
ration was reached. The psychiatric condition of 
the participants of the current interview study was 
not assessed again at the start of this study.
Data gathering and analysis
Individual semistructured interviews were con-
ducted in January and February 2014. According 
to the preference of all participants, we conducted 
interviews by telephone. Each interview lasted 
15–20 min. RE (physician, trained interviewer) 
performed the interviews. All interviews were 
recorded and transcribed verbatim. Thematic 
analysis was carried out inductively using a quali-
tative software package (Atlas.ti, version 7.1.5). 
Analysis began once data collection commenced 
as an iterative process, based on the ‘constant 
comparative method’.21 Coding was carried out 
independently by two of the authors (RE, PL), 
followed by a series of discussions to derive the 
coding framework. When no consensus could be 
reached, a third author (AS) was consulted. 
Exemplary quotations were selected to demon-
strate the findings, followed by a short description 
of the cited participant: gender, age, acceptance 
or rejection of the discontinuation advice given in 
the RCT, and actual discontinuation of antide-
pressant use.
Results
We interviewed 16 participants; 11 were female 
(69%), mean age was 57 years with a range of 
31–76 (women) and 51–79 (men). Seven partici-
pants intended to comply with the discontinua-
tion advice during the RCT; five of these actually 
discontinued their antidepressant (during or after 
the RCT). The participants used a great variety of 
antidepressants before the discontinuation advice 
in the RCT (Table 1).
Several themes emerged, which we have grouped 
into barriers, facilitators, and ambivalence 
towards discontinuing long-term antidepressants 
(Table 2). After 14 participants, no new codes 
emerged.
Barriers
Participants mentioned the following factors that 
complicated discontinuation of the antidepres-
sant: attributions, fears, and prior attempts.
Attributions. Participants described their antide-
pressant use as supplying an otherwise deficient 
substance. This substance was perceived as 
‘needed’ to function normally as this deficiency 
caused the depression, resulting in the acceptance 
of lifelong dependency. The comparison with dia-
betes was also made.
‘I just need it. For me this isn’t a psychological illness, 
it’s physical. And my body isn’t able to make enough 
serotonin, so I take the pill to supply it.’ (ID 129: 
female, 66 year, rejected advice and did not 
discontinue).
‘She (the GP) told me, you should see it like you have a 
deficiency in your brain, you miss a certain substance 
and the medicine supplies it. She told me, it’s just like 
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someone with diabetes, who needs insulin for the rest of 
their life. Well, I kind of believe that, so never questioned 
my use since.’ (ID 302: female, 74 year, rejected 
advice and did not discontinue).
Another attribution that played a role was the 
belief to be suffering from a chronic condition, 
and thus in need of lifelong medication. 
Antidepressants were also described as being a 
natural and bodily substance, thus ‘it surely could 
do no harm.’
Fear. Fear of recurrence or relapse was a great 
barrier to attempt to discontinue. Participants 
were afraid of reliving the negative feelings they 
had in the past, and anticipated this recurrence if 
they were to discontinue.
‘That’s my biggest fear. The misery I was in, before I got 
these medicines. I never want to relive that. I never want 
to go back to how I felt then. And because of this fear, I 
just can’t attempt to stop them.’ (ID 129: female, 
66 year, rejected advice and did not discontinue).
‘. . ..if I would remain to feel well, I would quit 
tomorrow, but . . . to go through the hell I went through 
again? No.’ (ID 170: female, 64 year, rejected advice 
and did not discontinue).
Others described the fear of disturbing the bal-
ance or equilibrium they had achieved.
‘I have found a balance, emotionally, that is. Well, and 
I don’t want to disturb this balance.’ (ID 262: male, 
63 year, rejected advice and did not discontinue).
‘Well, I’m feeling very well, I am very stable. I’m in 
harmony, I don’t have any mood swings or anything. I 
don’t think I could feel any better than I do now. Also, 
mentally. So, I won’t risk it. I won’t attempt it, maybe 
Table 1. Characteristics of participants.
Gender Age Intended to 
comply with 
discontinuation 
advice
Actually stopped 
antidepressant 
use
Successful 
discontinuation
Antidepressant 
before 
discontinuation 
advice
Female 64 no no no Clomipramine
Female 43 yes no no Sertraline
Female 43 yes yes no Fluvoxamine
Female 31 no no no Paroxetine
Female 62 no no no Amitriptyline
Female 50 no no no Fluoxetine
Male 66 yes yes no Venlafaxine
Male 57 no no no Paroxetine
Female 45 yes yes no Paroxetine
Male 79 yes ne no Fluvoxamine
Female 32 no no no Sertraline
Male 61 no yes no Citalopram
Male 51 yes yes yes Citalopram
Female 72 no no no Venlafaxine
Female 76 no no no Venlafaxine
Female 53 yes no no Paroxetine
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it would be successful, but I won’t dare to try.’ (ID 302: 
female, 74 year, rejected advice and did not 
discontinue).
Another fear was the effect an antidepressant dis-
continuation would have on their relationship 
with their partner.
‘I don’t really want to take the risk. If I stop with the 
antidepressant medication, that A the symptoms would 
come back, but also B there would be more tension in my 
relationship, and I would keep getting into a fight.’ (ID 
262: male, 63 year, rejected advice and did not 
discontinue).
‘She (my wife) really does understand that I would like to 
try to taper, it’s not like she doesn’t want me to. But she 
said please take the pills, because you’re so much easier to 
handle. . . ha-ha. So, I just keep taking them.’ (ID 219: 
male, 59 year, rejected advice and did not discontinue).
Prior attempts. Fears and attributions were some-
times fuelled by experiences during prior discon-
tinuation attempts. Because of the difficulty in 
tapering and discontinuation symptoms, attribu-
tions concerning lifelong need and anticipation 
fear were reconfirmed. Attempts to discontinue 
were frequently made without informing, or 
receiving guidance from, their GP.
‘Yeah, well, then (prior attempt) my tolerance level 
lowered, and I became agitated. I also had more feelings 
of loneliness and abandonment, so I didn’t feel well at all 
and didn’t know what to do. Yeah, that kept coming 
back. I started to think, what good is this? Why am I 
doing this? Why should I stop? Then I restarted the 
medication.’ (ID 262: male, 63 year, rejected advice 
and did not discontinue).
Facilitators
Mentioning the limited duration of antidepres-
sant usage at first prescription was found to facili-
tate the tapering process.
‘So, from the start I knew that we would stop (the 
antidepressant) as soon as it was possible.’ (ID 186: 
male, 68 year, accepted advice but did not 
successfully discontinue).
Table 2. Emerging themes concerning the discontinuation of long-term antidepressant use.
Barriers Facilitators Ambivalence
Attributions Information Trade-off between barriers and 
facilitators
 Serotonin deficiency Known limited duration of use at 
first prescription
 
 Chronic condition Professional’s opinion use is no 
longer indicated
 
 Antidepressants do no harm  
Fear Fear Lack of motivation despite no 
barriers
 Recurrence or relapse Addiction  
 Disturb the balance Stigma  
 Effect on relationships Shame  
 Long-term adverse effects  
Prior attempts Self-confidence in success  
 Trust in GP (safety net, 
counsellor)
 
 Practical motives (e.g. driver’s 
license)
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‘My GP made it very clear, it (the antidepressant) is 
only a temporary solution, it will help, but the problem 
lies elsewhere.’ (ID 228: female, 47 year, accepted 
advice but did not successfully discontinue).
The antidepressant discontinuation advice was 
seen by some as the nudge needed to start taper-
ing their antidepressant.
‘. . . if you get the advice, that it should be possible, then 
you start to think, maybe I should try. Because you do 
want to live without. It gave me the extra nudge that I 
needed to give it a try. I already questioned my use 
frequently, like, you think that this tablet works well, but 
you’re not sure, are you? I’m glad I participated in this 
study, that I got the validation I needed, that I could do 
without.’ (ID 165: female, 45 year, accepted advice 
and successfully discontinued).
‘Without the advice, I would just have kept taking the 
medication.’ (ID 186: male, 68 year, accepted advice 
but did not successfully discontinue).
The confidence a participant had beforehand in 
the success of a discontinuation attempt was 
important. If the participant could be convinced 
the attempt would be successful, the fear to dis-
continue would diminish. The GP played an 
important role in this, both as a ‘safety net’ and as 
a ‘partner or counselor during the attempt’. 
Patients need to have trust in their GP to be able 
to commence a discontinuation attempt.
‘. . . . And that my GP is willing to say, no we won’t 
wait and see, but will take my symptoms seriously. Then 
I thought, now I can try (to taper), if I have a kind of 
safety net. I had more confidence in myself, so I gave it 
a go. It was scary.’ (ID 238: female, 34 year, rejected 
advice and did not discontinue).
As a motivator to discontinue their antidepressant 
use, participants mentioned fear of addiction. In 
addition, they felt it could not be healthy to use 
antidepressants forever and were worried about 
long-term adverse effects. Other motivating fac-
tors to discontinue were the amount of stigma 
and shame the participant felt by having to rely on 
antidepressants. The ability to be able to function 
on their own without being dependent of antide-
pressants was also a contributor.
‘I really wanted to be able to do it on my own. To live my 
life and not stay standing because of medication.’ (ID 239: 
female, 34 year, rejected the advice and did not 
discontinue).
One participant mentioned a practical reason why 
she wanted to discontinue. She experienced the 
hassle of the medical examination to extend her 
driver’s license, after declaring to use antidepres-
sant medication.
Ambivalence
We found a great ambivalence in the use of anti-
depressants. Some participants described the 
struggle between barriers and motivators to dis-
continue, but others did not recognize this strug-
gle when prompted. These participants had no 
motivation to discontinue, despite the lack of any 
barriers.
‘Well, you just can keep the medicine as maintenance 
therapy. But I haven’t had any symptoms for a long 
while, so there isn’t really any reason not to try to stop 
using it, is there? Sometimes I even skip one, just because 
I don’t feel taking it. But I do always call for a repeat 
prescription. I just haven’t done it, stop completely.’ (ID 
161: female, 45 year, accepted advice but did not 
successfully discontinue).
Discussion
We found barriers and facilitators to discontinue 
long-term antidepressant use without a proper 
indication. Fear (of recurrence, relapse, or to dis-
turb the equilibrium) was the most prominent 
barrier, and prior attempts fuelled these anticipa-
tions. These fears have previously been described 
in the literature for all antidepressant users,15–17 
and our study confirmed that long-term antide-
pressant users, who, according to the guidelines 
do not have an indication, and, accordingly, could 
consider discontinuation, face the same fears. As 
facilitators for an attempt, participants mentioned 
a known limited duration of usage at the time of 
starting the drug and the confidence in a success-
ful attempt, which could be enforced by guidance 
and reassurance by the GP. Also, participants felt 
that being able to live without their antidepres-
sants empowered them. Another qualitative study 
has shown that GPs also face fears in the process 
of discontinuation.23
Another important barrier was the notion that 
antidepressants are necessary to supply the defi-
cient serotonin. This serotonin deficiency resulted 
in patients expecting continued use of their 
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medication. Presumably this is the result of the 
explanation the GPs gave to their patients at first 
prescription, or at least what patients (choose to) 
remember. The biological model for depression 
seems to backfire,22 making it difficult to per-
suade the patient to discontinue the drug. This is 
an important and new finding. GPs must keep 
this in mind while explaining the course of treat-
ment for depressive and anxiety disorders. On the 
other hand, uneasiness with the perception of a 
biological cause could enhance attempts to stop 
antidepressants.23
In addition, we also found ambivalence towards 
antidepressant use. With the lack of motivation to 
discontinue, most participants just kept on using 
them, even when no barriers were apparent. 
Malpass and colleagues describe that patients find 
a balance between pros and cons.14 In this study, 
we also found this trade-off. Participants described 
motivators and facilitators to discontinue, but 
these were overruled by the barriers they perceived 
and thus did not actually discontinue. Our results 
also show that for some, but not all, participants 
this is a conscious choice. The willingness to dis-
continue seems to be important. Some participants 
only needed a little ‘nudge’, while others plainly 
refused to discontinue their antidepressant. The 
importance of willingness to discontinue has also 
been indicated in long-term benzodiazepine use.24 
Where benzodiazepines are seen as addictive, anti-
depressants are not. However, some patients do 
seem psychologically dependant.
Strengths and limitations. This paper contributes 
to a relatively small amount of literature on long-
term antidepressant usage. As part of the RCT, 
the sample was limited to participants of that 
study: long-term antidepressant users without a 
current clinical indication for this usage, who had 
received a recommendation to discontinue their 
use. By purposive sampling, we were able to pro-
vide a good mix of participants reluctant or will-
ing to discontinue long-term antidepressants, in 
addition to gender and age. This resulted in a 
study of patients who are usually hard to reach in 
mental health research but are very relevant to 
general practice.
Prior to the interview for the qualitative study we 
did not assess the psychiatric condition of the par-
ticipants again. During the intervention in the 
RCT, participants were not depressed, but they 
could have developed a new depressive episode 
by the time of the qualitative interview. This 
could have influenced the results of the qualita-
tive interview in the sense that they would report 
more facilitators.
Long-term antidepressant users are a selection of 
patients prescribed antidepressants, who have 
already gone through the process of acceptance 
and adherence to this medication. We can imag-
ine these patients have found a balance between 
pros and cons, thus resulting in their long-term 
use. Therefore, the findings in this study cannot 
be extrapolated to all antidepressant users. In 
addition, as with all qualitative research, our find-
ings may not be exhaustive.
Recommendations for clinical practice. At first 
prescription, GPs should realize that, by explain-
ing the effects of antidepressants as a supplement 
for a deficiency in serotonin, patients could per-
ceive antidepressants as a lifelong necessity. Dis-
cussing an anticipated duration of antidepressant 
usage at first prescription could facilitate a dis-
continuation attempt in the future. Before recom-
mending the discontinuation of long-term 
antidepressant use without indication, an explo-
ration of existing fears and expectations is con-
structive. Previous attempts to taper could have 
taken place without the knowledge of the GP, and 
without any guidance or counseling, possibly 
resulting in anticipation fear. Because patients 
and GPs have different expectations concerning 
the initiative for discontinuation and the time for 
support necessary during/after discontinuation, it 
is important to discuss these issues, both at the 
start of treatment and at the start of discontinua-
tion.23 Cognitive therapy could possibly be used 
as a supportive therapy before the start of the 
tapering process when fear is apparent; one study 
of patients with anxiety disorders showed that 
cognitive behavioral therapy (CBT) beginning at 
the start of discontinuation did not prevent 
relapse.25 Stopping antidepressant use is difficult, 
and many patients experience a relapse.25,26 Thus, 
the patient’s fear might be totally justified in the 
light of problems experienced during prior 
attempts. A further issue in discontinuing antide-
pressants is the tapering scheme itself. Many 
tapering schemes advocate a duration between 2 
and 4 weeks with linear reduction of the dose. 
Because many patients experience withdrawal 
symptoms several weeks after the discontinuation, 
which might be understood by the specific rela-
tion between the dose of the selective serotonin 
reuptake inhibitor (SSRI) and the level of sero-
tonin transporters in the brain, a hyperbolic taper 
Therapeutic Advances in Psychopharmacology 9
8 journals.sagepub.com/home/tpp
scheme makes more sense than a linear scheme. 
In a hyperbolic scheme, the taper period is much 
longer while the dose reductions in the final weeks 
are very small.27
Conclusion
Discontinuing long-term antidepressant usage with-
out a current indication is difficult. Fear plays an 
important role. The serotonin deficiency as expla-
nation for antidepressant effectiveness promotes 
life-long use and hinders discontinuation of antide-
pressant treatment. The prospect of discontinuation 
at first prescription can facilitate a future discontin-
uation attempt. GPs should be aware of patients’ 
fears, expectations, and attributions towards antide-
pressant use/discontinuation when discussing anti-
depressant discontinuation. GPs also should be 
aware of new developments in tapering methods.
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